Soleno Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Soleno Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-11.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-11.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Nov 08

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Oct 10

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Dec 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SLNO şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SLNO şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Soleno Therapeutics Piyasaya Karşı Temettü Getirisi

SLNO temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SLNO)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (SLNO) (3 yıla kadar)	n/a

Önemli Temettü: SLNO şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SLNO şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SLNO şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SLNO herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Soleno Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Forecast to breakeven in 2026

Price target increased by 8.0% to US$73.57

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

President recently sold US$1.1m worth of stock

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold US$800k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Independent Chairman exercised options to buy US$2.6m worth of stock.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold US$785k worth of stock

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Price target lowered to US$7.00

New 90-day low: US$1.38

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: US$2.74

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Soleno Therapeutics: Could Be Big Fish In The Small Pond

New 90-day high: US$2.10

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation